Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

Researchers have explored potential treatment that could bring unexpected relief to people living with severe vision loss.The ...

The first-ever patient to receive groundbreaking eye injection treatment broke her silence after regaining her ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

Seven different postoperative complications occurred two to four times more often in patients who had a history of intravitreal drug injections as compared with those who did not. Among complications ...

NEW YORK, NY-- A new study suggests that eye drops developed by Columbia University researchers could be a more effective–and comfortable–therapy for a common eye disease currently treated with ...

People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...